• SPX
  • $5,751.13
  • 0.97 %
  • $55.19
  • DJI
  • $42,080.37
  • 0.3 %
  • $126.13
  • N225
  • $39,277.96
  • 0.87 %
  • $340.42
  • FTSE
  • $8,201.09
  • 0.13 %
  • $10.48
  • IXIC
  • $18,182.92
  • 1.45 %
  • $259.01
Ardelyx, Inc. (ARDX) Stock Price, News & Analysis

Ardelyx, Inc. (ARDX) Stock Price, News & Analysis

Currency in USD Disclaimer

$5.95

-$0.18

(-2.94%)

Day's range
$5.95
Day's range
$6.19
50-day range
$5.32
Day's range
$7.18
  • Country: US
  • ISIN: US0396971071
52 wk range
$3.16
Day's range
$10.13


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 1.48
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (ARDX)
  • Company Ardelyx, Inc.
  • Price $5.95
  • Changes Percentage (-2.94%)
  • Change -$0.18
  • Day Low $5.95
  • Day High $6.19
  • Year High $10.13

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 10/28/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $9.00
  • High Stock Price Target $15.00
  • Low Stock Price Target $2.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.28
  • Trailing P/E Ratio -23.04
  • Forward P/E Ratio -23.04
  • P/E Growth -23.04
  • Net Income $-66,067,000

Income Statement

Quarterly

Annual

Latest News of ARDX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.